Introduction
Diabetic neuropathy (DN) is one of the most common peripheral nervous system disorders. It affects 16% of individuals with type I (young onset) diabetes and 25-26% of individuals with type II (late onset) diabetes [1] . Pain and numbness of the feet and, in advanced cases, weakness in the feet or hands are the usual symptoms. These symptoms are typically more prominent in the lower limbs. The skin in the affected areas is sensitive to touch (hyperesthesia); sometimes touch evokes pain (allodynia). The pain of diabetic neuropathy may develop spontaneously or may be provoked by touch or motion. Pain often interferes with patient's rest and sleep and has typical characteristics of a neuropathic pain i.e having a sharp and burning quality. Dorsum of the foot and toes are most commonly affected in diabetic neuropathy. On examination, the patients demonstrate decreased sensations (heat, cold, touch, position) in the affected limb. Diabetic neuropathy (DN) is usually bilateral and presents in form of a polyneuropathy. In more recent years, other agents have been found helpful in relieving the pain of DN in both humans and animal models. In human, the efficacy cannabinoids inhalation [4] , to relive the pain of diabetic neuropathy has been shown in a small randomized, double blind, placebocontrolled study. In rats, several studies suggested that epigallocatechin-3-gallate (EGCG), the active component of green tea, can relieve neuropathic pain including the pain of DN [5] . 
Method of the Review
The published literature on the use of botulinum toxins in postherpetic neuralgia was reviewed, using Medline and Ovis SP search engines. The search included all English manuscripts published between January 1,1989 (the year botulinum toxin was introduced into the market) to February 1 st ,2019. The search words included botulinum toxin, botulinum neurotoxin, diabetes, diabetic neuropathy and neuropathic pain.
Results
This search identified a total of forty five manuscripts, of which 5 manuscripts were directly relevant to the search subject (Table 2) . Four manuscripts represented, randomized, double-blind, placebo-controlled clinical trials. Three of these four studies were of parallel design, while one had a cross-over design. All Page: 3 www.raftpubs.com studies used type A toxin-three used Botox, one Xeomin and one Dysport. Of four studies with neuropathic pain (foot), the mode of injection was intradermal in three; the toxin was employed in small doses using a grid-like pattern over the dorsum of the foot. In one patient, the toxin (Botox) was injected directly into the lumbar plexus. One double -blind study evaluated the efficacy of intramuscular toxin injection in relieving calf and foot cramps associated with diabetic neuropathy (table 2). The toxin dose used was 100 units in four and 50 units in one study. The response of neuropathic pain was evaluated by visual analogue scale (0-10) and that of muscle cramps by changes in frequency and intensity of cramps. All 4 studies of neuropathic pain in DN demonstrated significant pain relief after botulinum toxin treatment. In the study of Restivo et al. [7, 8] , intramuscular injection of the toxin reduced the frequency and intensity of cramps substantially. None of the studies demonstrated any serious adverse effects. 
Conclusion
The data from high quality studies of Botulinum toxin A in DN is encouraging and suggest the efficacy of all type A toxins in relieving both neuropathic pain and painful cramps in DN. Lack of significant adverse effects, prolonged effect (3-4 months) after one set of injections versus daily use of oral analgesic agents, makes botulinum toxin treatment desirable to patients. Larger randomized clinical trials are necessary to
